# EDGAR Filing Document

**Accession Number:** 0001012477
**File Stem:** 0001104659-26-018282
**Filing Date:** 2026-2
**Character Count:** 3177
**Document Hash:** afdf450b20dc008194cb56cb6e14742c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-018282.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0001104659-26-018282

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**EFFECTIVENESS DATE**: 20260223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVADEL PHARMACEUTICALS PLC
- **CENTRAL INDEX KEY:** 0001012477
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37977
- **FILM NUMBER:** 26661970

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 10 EARLSFORT TERRACE
- **CITY:** DUBLIN 2
- **PROVINCE COUNTRY:** L2
- **ZIP:** D02 T380
- **BUSINESS PHONE:** 636-449-1830

**MAIL ADDRESS:**
- **STREET 1:** 16640 CHESTERFIELD GROVE ROAD
- **STREET 2:** SUITE 200
- **CITY:** CHESTERFIELD
- **STATE:** MO
- **ZIP:** 63005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLAMEL TECHNOLOGIES SA
- **DATE OF NAME CHANGE:** 19960422

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION<br> UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR<br> SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF<br> THE SECURITIES EXCHANGE ACT OF 1934.**

**Commission File Number 001-37977**

---

| |
|:---|
| **AVADEL PHARMACEUTICALS PLC** |
| (Exact name of registrant as specified in its charter) |
| **10 Earlsfort Terrace**<br> **Dublin 2, Ireland, D02 T380**<br> **+353-1-901-5201** |
| (Address, including zip code, and telephone number,<br> including area code, of registrant's principal executive offices)<br>**c/o Alkermes plc**<br> **David J. Gaffin, Esq.**<br> **Connaught House**<br> **1 Burlington Road**<br> **Dublin 4, Ireland D04 C5Y6**<br> **(Name and address of agent for service)**<br>**+353-1-772-8000**<br> **(Telephone number, including area code, of agent for service)**<br>|
| **Ordinary Shares, nominal value $0.01 per share** |
| (Title of each class of securities covered by this Form) |
| (Titles of all other classes of securities for which<br> a duty to file reports under section 13(a) or 15(d) remains) |

---

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | x |
| Rule 12g-4(a)(2) | ¨ |
| Rule 12h-3(b)(1)(i) | x |
| Rule 12h-3(b)(1)(ii) | ¨ |
| Rule 15d-6 | ¨ |
| Rule 15d-22(b) | ¨ |

---

Approximate number of holders of record as of the certification or notice date: One (1) holder.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Avadel Pharmaceuticals plc has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: February 23, 2026 | By: | /s/ Declan O'Connor |
|  | Name: | Declan O'Connor |
|  | Title: | Director |

---